Efficacy of Bioactive Collagen Peptide Compared to Glucosamine and Chondroitin Sulphate in Grade I-III Knee Osteoarthritis
Key facts
- Who runs it
- Liaquat National Hospital & Medical College
- Where
- Pakistan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 150 people enrolled
- Started
- 1 Jun 2023
- Ended
- 17 Aug 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Bioactive Collagen Peptide
- Glucosamine and Chondroitin Sulphate
- Record updated
- 10 August 2026
Who can take part
- Age
- 40 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Adults aged 40 years and older
- Clinical diagnosis of knee osteoarthritis according to the American College of Rheumatology (ACR) criteria
- Radiographic Kellgren-Lawrence grade I, II, or III osteoarthritis in at least one knee
- Willing and able to provide written informed consent
- Willing to comply with the study protocol and attend all follow-up visits
Who cannot take part
- Previous use of collagen peptide or glucosamine-chondroitin supplements before enrollment
- Inflammatory arthritis, including rheumatoid arthritis, systemic lupus erythematosus, spondyloarthropathy, or polymyalgia rheumatica
- Post-traumatic osteoarthritis
- Patients with hyperuricemia
- Pregnancy or breastfeeding
- Inability or unwillingness to comply with study procedures or complete follow-up
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Brief Summary
Read full original descriptionShow less
The goal of this clinical trial is to learn whether bioactive collagen peptide works as well as glucosamine and chondroitin sulphate for improving pain, stiffness, physical function, and quality of life in adults with mild to moderate knee osteoarthritis (Kellgren-Lawrence grades I to III).
The main questions it aims to answer are:
Does bioactive collagen peptide improve knee pain, stiffness, and physical function over 12 weeks? Does bioactive collagen peptide improve health-related quality of life? Is bioactive collagen peptide as safe and effective as glucosamine and chondroitin sulphate for treating knee osteoarthritis?
Researchers will compare bioactive collagen peptide with glucosamine and chondroitin sulphate to determine whether one treatment provides greater improvement in symptoms and quality of life.
Participants will:
Be randomly assigned to receive either bioactive collagen peptide once daily or glucosamine and chondroitin sulphate twice daily for 12 weeks.
Attend study visits at the start of the study and again at 6 and 12 weeks. Complete questionnaires about their knee pain, stiffness, physical function, and overall health-related quality of life at each visit.
Be monitored for treatment adherence, use of rescue pain medication, and any side effects throughout the study.
The information from this study may help healthcare providers better understand whether bioactive collagen peptide is an effective and safe non-surgical treatment option for people with symptomatic knee osteoarthritis.
The 2 groups in the trial
- Bioactive Collagen Peptide (Movgen®)Treatment being tested
Oral bioactive collagen peptide Fish collagen 4000 mg + Curcuma longa extract 250 mg Dose: 8 g once daily Duration: 12 weeks
Treatment: Bioactive Collagen Peptide
- Glucosamine and Chondroitin Sulphate (Gebon Plus®)Existing treatment, for comparison
Glucosamine sulphate 400 mg Chondroitin sulphate 300 mg Methylsulfonylmethane 200 mg Hyaluronic acid 100 mg Boswellia serrata extract 40 mg Smilax chinensis extract 30 mg Curcuma longa extract 30 mg Dose: Twice daily Duration: 12 weeks
Treatment: Glucosamine and Chondroitin Sulphate
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Bioactive Collagen Peptide Versus Glucosamine and Chondroitin Sulphate in Grade I-III Knee Osteoarthritis: A Randomized Controlled Trial
- Record updated
- 10 August 2026